• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·AMGN
Held by 3 Gurus
Share

Amgen Inc. Stocks

$ 439.26Last Updated 23.10.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

$ 237.48B

$ 439.26
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.1%

Change

+0.02%

Fund

CITADEL ADVISORS LLC

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.01%

Fund

Bridgewater Associates

Steven Cohen

Portfolio Weight (%)

0.0%

Change

-0.01%

Fund

Point72 Asset Management, L.P.

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.1%+0.02%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.01%
Steven CohenPoint72 Asset Management, L.P.0.0%-0.01%

Latest news

26.10.2026 15:22

Morning in New York: Focus on the Oil Price Pullback Ahead of the Fed Meeting

16.10.2026 08:00

Pharmaceutical companies benefited from the sell-off in the AI sector. Which stocks are nearing their all-time highs?

09.09.2026 17:04

Mid-cap biotech Dyne becomes collateral damage of another Novartis pipeline setback

09.09.2026 15:41

Morning in New York: Brent Puts Investors to the Test

08.09.2026 16:07

Pharmaceutical giant Novartis is on track for its worst slump in six years following a series of failed trials

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, reasonably

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of AMGN is 405 and suggests 7.77% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.10.2026 17:10

Betting Against the Euro: What Could Threaten This Currency

26.10.2026 16:33

Meta plans to raise up to $95 billion through a stock sale to fund its AI initiatives

26.10.2026 16:03

Two funds linked to the AI boom are being shut down in the U.S. They had been in operation for several months.

26.10.2026 15:22

Morning in New York: Focus on the Oil Price Pullback Ahead of the Fed Meeting

26.10.2026 15:03

Goldman has downgraded its outlook for the market, which is considered a barometer for AI. Is this a signal to investors?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026